ADVM-022 (Ixoberogene Soroparvovec) is an investigational gene therapy being studied for the treatment of Wet Age-related Macular Degeneration (Wet AMD).
| Drug class | Gene Therapy |
|---|---|
| Type | Single |
| Forms | Intravitreal Injection |
| Common strength | Per dose |
| Prescription status | Investigational |
What ADVM-022 (Ixoberogene Soroparvovec) is used for
ADVM-022 (Ixoberogene Soroparvovec) is an investigational medicine currently being studied for the treatment of:
- Wet Age-related Macular Degeneration (Wet AMD)
It is important to note that this medicine is still under investigation and is not yet approved or routinely available in India. Your ophthalmologist can discuss approved and available treatment options for Wet AMD.
How it works
ADVM-022 (Ixoberogene Soroparvovec) is a type of gene therapy. Gene therapy works by introducing genetic material into the body’s cells to help treat a disease. In the case of ADVM-022, it is designed to enable the eye to produce its own anti-VEGF medicine continuously. This sustained production of anti-VEGF medicine aims to reduce the need for frequent injections that are typically required for Wet AMD treatment.
How it’s used
ADVM-022 (Ixoberogene Soroparvovec) is administered as a single intravitreal injection. This means it is given as an injection directly into the vitreous humour, the jelly-like substance that fills the centre of your eye. This procedure is performed by a retina specialist.
Since this is an investigational medicine, the exact dosing and administration protocols are part of ongoing clinical trials. If you are participating in a clinical trial for ADVM-022, your medical team will provide detailed instructions and care.
Always follow your ophthalmologist’s exact instructions.
Brands in India
Hospital-prepared or not marketed as a retail brand in India.
Please note
Given as an injection inside the eye by a retina specialist. After any intravitreal injection, seek help IMMEDIATELY if you develop increasing pain, redness, sensitivity to light or a drop in vision — these can be signs of a serious infection (endophthalmitis). Not currently approved or routinely available in India — included for reference; ask your ophthalmologist about approved alternatives.
Precautions & side effects
ADVM-022 (Ixoberogene Soroparvovec) is an investigational medicine, meaning it is still undergoing studies to determine its safety and effectiveness. Therefore, specific precautions and side effects are being carefully monitored in clinical trials.
However, it is crucial to understand that any intravitreal injection (an injection given inside the eye) carries certain risks. After receiving an intravitreal injection, it is extremely important to seek medical help IMMEDIATELY if you experience any of the following symptoms:
- Increasing pain in the eye
- Increased redness of the eye
- Increased sensitivity to light
- A sudden drop or change in your vision
These symptoms can be signs of a serious eye infection called endophthalmitis, which requires urgent medical attention to prevent severe vision loss.
As this medicine is not currently approved or routinely available in India, it is included here for reference. Please discuss with your ophthalmologist about approved and available alternatives for your condition.
Understanding Wet Age-related Macular Degeneration (Wet AMD)
Wet Age-related Macular Degeneration (Wet AMD) is a common eye condition that affects the macula, the central part of your retina responsible for sharp, detailed vision needed for tasks like reading and recognising faces. In Wet AMD, abnormal blood vessels grow under the macula. These fragile vessels can leak fluid and blood, damaging the macula and leading to blurred vision, distorted vision (straight lines appearing wavy), or a blind spot in your central vision. If left untreated, Wet AMD can lead to severe and permanent vision loss. Early detection and timely treatment are crucial to preserve your eyesight. Regular eye check-ups, especially if you are over 50 or have a family history of AMD, are highly recommended.
Treatments for Wet AMD often involve medicines that block a substance called Vascular Endothelial Growth Factor (VEGF), which promotes the growth of these abnormal blood vessels. These anti-VEGF medicines are typically given as injections into the eye at regular intervals to control the disease and prevent further vision loss.
General Advice for Eye Injections and Eye Care
While ADVM-022 is an investigational gene therapy, it is administered as an injection into the eye. For any eye injection, it is vital to follow your doctor’s instructions carefully. After an eye injection, you might experience some mild discomfort, redness, or a feeling of something in your eye, which usually subsides within a day or two. It is normal to see some floaters (small spots or lines that drift across your vision) after an injection, but these should also lessen over time. Always keep your hands clean before touching your eyes or the area around them to prevent infections.
Maintain good eye hygiene by avoiding rubbing your eyes, especially after an injection. If you are prescribed any eye drops to use after the injection, ensure you use them exactly as directed. Store all eye medicines as instructed by your pharmacist or doctor, usually in a cool, dry place away from direct sunlight and out of reach of children.
When to Seek Immediate Medical Help
Your vision is precious, and it’s important to know when to seek urgent medical attention. After any eye procedure, including an intravitreal injection, certain symptoms could indicate a serious complication. You must contact your ophthalmologist or go to the nearest eye hospital IMMEDIATELY if you experience any of the following:
- Severe or increasing eye pain: Pain that gets worse or doesn’t go away.
- Significant increase in eye redness: More redness than usual, or redness that spreads.
- Extreme sensitivity to light (photophobia): Finding bright lights very uncomfortable or painful.
- A sudden and noticeable drop in your vision: Any new blurring, loss of vision, or a significant change in how clearly you see.
- New or worsening floaters or flashes of light: While some floaters are normal after an injection, a sudden increase or new flashes could be a concern.
These symptoms could be signs of a serious infection (like endophthalmitis) or other complications that require immediate treatment to protect your vision. Do not delay in seeking help.
Frequently asked questions
What is ADVM-022 (Ixoberogene Soroparvovec) used for?
ADVM-022 (Ixoberogene Soroparvovec) is an investigational gene therapy being studied for the treatment of Wet Age-related Macular Degeneration (Wet AMD).
How does ADVM-022 (Ixoberogene Soroparvovec) work?
ADVM-022 (Ixoberogene Soroparvovec) is a gene therapy designed to enable the eye to produce its own anti-VEGF medicine continuously. This aims to provide sustained treatment for Wet AMD and potentially reduce the need for frequent injections.
What are the common Indian brands for ADVM-022 (Ixoberogene Soroparvovec)?
ADVM-022 (Ixoberogene Soroparvovec) is currently an investigational medicine and does not have any retail brands available in India. It is not yet approved or routinely available.
How is ADVM-022 (Ixoberogene Soroparvovec) administered?
ADVM-022 (Ixoberogene Soroparvovec) is administered as a single intravitreal injection, meaning it is injected directly into the eye by a retina specialist.
Is a prescription needed for ADVM-022 (Ixoberogene Soroparvovec)?
As ADVM-022 (Ixoberogene Soroparvovec) is an investigational medicine, it is not available for prescription or routine use. It is currently only used in clinical trials under strict medical supervision.
What are the key precautions for ADVM-022 (Ixoberogene Soroparvovec)?
ADVM-022 (Ixoberogene Soroparvovec) is investigational. After any intravitreal injection, seek help IMMEDIATELY if you develop increasing pain, redness, sensitivity to light or a drop in vision – these can be signs of a serious infection (endophthalmitis). It is not currently approved or routinely available in India; ask your ophthalmologist about approved alternatives.
References
- Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration – PMC
- Diabetic Retinopathy – National Eye Institute
- Eye health – MedlinePlus (US National Library of Medicine)
- Eye health information – American Academy of Ophthalmology
- Blindness and vision impairment – World Health Organization
Medically reviewed by Dr. C Jagadesh Reddy, Chief Surgeon: Cornea, Cataract and Refractive Surgery — last reviewed 2026-07-28.
This page is for general education only and is not a substitute for professional medical advice, diagnosis or treatment. Never self-medicate or reuse an old prescription. Always consult a qualified ophthalmologist before starting, changing or stopping any eye medicine.